The U.S. Food and Drug Administration accepted VBI Vaccines Inc.'s investigational new drug application for VBI-1901, an immunotherapy to treat glioblastoma multiforme.

Glioblastoma multiforme is the most common and aggressive malignant primary brain tumors in humans.

VBI Vaccines intends to evaluate the drug in the second half of 2017 in a phase 1/2a clinical trial in patients with recurrent glioblastoma multiforme.